DK1301201T3 - Behandling af glycogenosis type II - Google Patents

Behandling af glycogenosis type II

Info

Publication number
DK1301201T3
DK1301201T3 DK01951000T DK01951000T DK1301201T3 DK 1301201 T3 DK1301201 T3 DK 1301201T3 DK 01951000 T DK01951000 T DK 01951000T DK 01951000 T DK01951000 T DK 01951000T DK 1301201 T3 DK1301201 T3 DK 1301201T3
Authority
DK
Denmark
Prior art keywords
treatment
glycogenosis type
storage disease
disease type
glycogen storage
Prior art date
Application number
DK01951000T
Other languages
Danish (da)
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1301201(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of DK1301201T3 publication Critical patent/DK1301201T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01951000T 2000-07-18 2001-07-10 Behandling af glycogenosis type II DK1301201T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
PCT/US2001/021651 WO2002005841A1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii

Publications (1)

Publication Number Publication Date
DK1301201T3 true DK1301201T3 (da) 2007-04-02

Family

ID=22818451

Family Applications (5)

Application Number Title Priority Date Filing Date
DK07001091.3T DK1782825T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK01951000T DK1301201T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenosis type II
DK18194771.4T DK3449934T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK14167882.1T DK2767291T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II
DK16178390.7T DK3108895T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07001091.3T DK1782825T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK18194771.4T DK3449934T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK14167882.1T DK2767291T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II
DK16178390.7T DK3108895T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II

Country Status (18)

Country Link
US (10) US7056712B2 (el)
EP (4) EP2767291B1 (el)
JP (10) JP5113312B2 (el)
AT (1) ATE355075T1 (el)
AU (3) AU7194101A (el)
BR (1) BR0113006A (el)
CA (1) CA2416492C (el)
CY (2) CY1120977T1 (el)
DE (1) DE60126947T2 (el)
DK (5) DK1782825T3 (el)
ES (5) ES2700865T3 (el)
HK (3) HK1054690A1 (el)
LT (3) LT3449934T (el)
MX (1) MXPA03000474A (el)
PT (5) PT3108895T (el)
SI (3) SI3449934T1 (el)
TW (1) TWI280882B (el)
WO (1) WO2002005841A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2767291B1 (en) * 2000-07-18 2016-09-14 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
JP4641705B2 (ja) * 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) * 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
ATE521701T1 (de) * 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
JP4914224B2 (ja) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP1773401B1 (en) * 2004-06-21 2013-01-02 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
EP3778652A1 (en) * 2008-05-07 2021-02-17 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
PT2318037E (pt) 2008-07-08 2015-05-20 Univ Duke Método de tratamento da doença de armazenamento de glicogénio
EP3075386B1 (en) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
CN105189542A (zh) 2013-02-20 2015-12-23 瓦莱里昂治疗有限责任公司 用于治疗庞贝氏症的方法和组合物
SG11201509419QA (en) * 2013-05-15 2015-12-30 Univ Minnesota Adeno-associated virus mediated gene transfer to the central nervous system
KR102455814B1 (ko) 2014-09-30 2022-10-18 아미쿠스 세라퓨틱스, 인코포레이티드 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제
WO2016178431A1 (ja) * 2015-05-07 2016-11-10 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
MA44747A (fr) * 2015-08-31 2019-03-06 Univ Duke Méthodes et compositions pour le traitement de troubles associés à une accumulation du glycogène cytoplasmique
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
MX2018008185A (es) 2015-12-30 2018-08-28 Amicus Therapeutics Inc Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.
WO2017173059A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
AU2017239641A1 (en) 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
IL262211B2 (en) 2016-04-15 2024-01-01 Univ Pennsylvania Gene therapy for the treatment of type II mucositis
BR112020005249A2 (pt) 2017-09-22 2020-09-24 The Trustees Of The University Of Pennsylvania terapia de gene para tratar mucopolissacaridose tipo ii
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) * 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CN1300323A (zh) 1998-05-13 2001-06-20 加州大学洛杉矶分校港口研究和教育院 重组α－L－艾杜糖苷酸酶,其生产和纯化的方法以及治疗其缺乏导致的疾病的方法
DE69939705D1 (de) * 1998-12-07 2008-11-20 Genzyme Corp Behandlung der pompeschen krankheit
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
EP2767291B1 (en) * 2000-07-18 2016-09-14 Duke University Treatment of glycogen storage disease type II
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
JP4914224B2 (ja) * 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
EP1301201B1 (en) 2007-02-28
DE60126947T2 (de) 2007-10-31
JP2020019822A (ja) 2020-02-06
PT3108895T (pt) 2018-12-18
EP1301201A1 (en) 2003-04-16
ES2799882T3 (es) 2020-12-22
EP2767291A3 (en) 2014-10-08
EP2767291B1 (en) 2016-09-14
CA2416492A1 (en) 2002-01-24
SI3449934T1 (sl) 2020-09-30
CY1123084T1 (el) 2021-10-29
DK3449934T3 (da) 2020-06-29
US20130195834A1 (en) 2013-08-01
DE60126947D1 (de) 2007-04-12
WO2002005841A1 (en) 2002-01-24
JP2018199721A (ja) 2018-12-20
US20150004152A1 (en) 2015-01-01
JP2018002749A (ja) 2018-01-11
AU2001271941B2 (en) 2007-03-01
JP2016056206A (ja) 2016-04-21
LT2767291T (lt) 2016-11-25
US20080175833A1 (en) 2008-07-24
JP2013231081A (ja) 2013-11-14
US20210169996A1 (en) 2021-06-10
ATE355075T1 (de) 2006-03-15
HK1054690A1 (en) 2003-12-12
BR0113006A (pt) 2004-10-19
EP3449934B1 (en) 2020-05-20
DK3108895T3 (en) 2018-11-26
MXPA03000474A (es) 2003-10-06
JP2004503598A (ja) 2004-02-05
JP2014185187A (ja) 2014-10-02
SI3108895T1 (sl) 2019-01-31
JP2017137357A (ja) 2017-08-10
DK2767291T3 (en) 2016-12-05
JP5792774B2 (ja) 2015-10-14
US8900552B2 (en) 2014-12-02
EP3449934A1 (en) 2019-03-06
US20050123531A1 (en) 2005-06-09
US9907839B2 (en) 2018-03-06
EP3108895B1 (en) 2018-09-19
ES2599401T3 (es) 2017-02-01
PT3449934T (pt) 2020-06-25
ES2700865T3 (es) 2019-02-19
TWI280882B (en) 2007-05-11
LT3449934T (lt) 2020-08-10
SI2767291T1 (sl) 2016-11-30
PT1782825E (pt) 2014-11-04
ES2523024T3 (es) 2014-11-20
LT3108895T (lt) 2018-11-26
JP5113312B2 (ja) 2013-01-09
DK1782825T3 (da) 2014-11-03
EP2767291A2 (en) 2014-08-20
US20160184410A1 (en) 2016-06-30
CA2416492C (en) 2008-04-29
US20120058132A1 (en) 2012-03-08
US7056712B2 (en) 2006-06-06
EP3108895A1 (en) 2016-12-28
US9370556B2 (en) 2016-06-21
US20020110551A1 (en) 2002-08-15
AU2010200487A1 (en) 2010-03-04
JP6163216B2 (ja) 2017-07-12
ES2277931T3 (es) 2007-08-01
US20180185457A1 (en) 2018-07-05
US10792341B2 (en) 2020-10-06
AU7194101A (en) 2002-01-30
JP2012006953A (ja) 2012-01-12
US20100254966A1 (en) 2010-10-07
HK1197656A1 (zh) 2015-02-06
PT2767291T (pt) 2016-10-25
JP2008081507A (ja) 2008-04-10
PT1301201E (pt) 2007-03-30
HK1103363A1 (en) 2007-12-21
CY1120977T1 (el) 2019-12-11

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
EA200201214A1 (ru) Замещенные тиоацетамиды
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
ATE245152T1 (de) Dioxocyclopentylhydroxamsäure
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
WO2003063787A3 (en) Non-steroidal analogs of 2-methoxyestradiol
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
SE0003476D0 (sv) Compounds
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
EA200501164A1 (ru) Индазоламиды с аналгетической активностью
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
ATE502639T1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel
CY1118235T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ii